Enthusiasm for immuno-oncology hasn't waned, and why should it? Companies like Bristol-Myers (NYSE:BMY), Merck (NYSE:MRK), and Roche (OTCQX:RHHBY)
have been producing clinical data from immuno-oncology drug trials
showing real improvements in response rates and survival in a range of
hard-to-treat cancer types. Although Celldex (NASDAQ:CLDX)
doesn't have the flavor-of-the-moment focus on CAR-T therapies, I would
argue that the company's collection of vaccines, ADCs, and targeted
antibodies is well worth a closer look from biotech investors.
Continue here:
Celldex Therapeutics Still Building Its Immuno-Oncology Story
No comments:
Post a Comment